Minerva Neurosciences Total Assets Growth & History (NERV)
Minerva Neurosciences's total assets was $98.0M for fiscal 2025.
View full Minerva Neurosciences company overviewMinerva Neurosciences annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $98.0M | $60.8M | +163.76% |
| 2024 | 2024-12-31 | $37.1M | −$19.8M | −34.72% |
| 2023 | 2023-12-31 | $56.9M | $1.8M | +3.29% |
| 2022 | 2022-12-31 | $55.1M | −$22.0M | −28.57% |
| 2021 | 2021-12-31 | $77.1M | $19.5M | +33.83% |
| 2020 | 2020-12-31 | $57.6M | −$19.9M | −25.64% |
| 2019 | 2019-12-31 | $77.5M | −$61.6M | −44.30% |
| 2018 | 2018-12-31 | $139.1M | −$44.6M | −24.26% |
| 2017 | 2017-12-31 | $183.7M | $50.8M | +38.18% |
| 2016 | 2016-12-31 | $132.9M | $50.4M | +60.99% |
| 2015 | 2015-12-31 | $82.6M | $14.1M | +20.64% |
| 2014 | 2014-12-31 | $68.5M | $39.3M | +134.62% |
| 2013 | 2013-12-31 | $29.2M | — | — |
Minerva Neurosciences quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $95.1M | $64.7M | +212.59% |
| Q1 2026 | 2026-03-31 | $94.0M | $61.2M | +186.68% |
| Q4 2025 | 2025-12-31 | $98.0M | $60.8M | +163.76% |
| Q3 2025 | 2025-09-30 | $28.1M | −$14.7M | −34.38% |
| Q2 2025 | 2025-06-30 | $30.4M | −$15.9M | −34.29% |
| Q1 2025 | 2025-03-31 | $32.8M | −$17.7M | −35.07% |
| Q4 2024 | 2024-12-31 | $37.1M | −$19.8M | −34.72% |
| Q3 2024 | 2024-09-30 | $42.8M | −$20.3M | −32.18% |
| Q2 2024 | 2024-06-30 | $46.3M | −$20.8M | −31.05% |
| Q1 2024 | 2024-03-31 | $50.5M | −$1.1M | −2.10% |
| Q4 2023 | 2023-12-31 | $56.9M | $1.8M | +3.29% |
| Q3 2023 | 2023-09-30 | $63.1M | $3.4M | +5.64% |
| Q2 2023 | 2023-06-30 | $67.1M | $2.2M | +3.35% |
| Q1 2023 | 2023-03-31 | $51.6M | −$19.0M | −26.94% |
| Q4 2022 | 2022-12-31 | $55.1M | −$22.0M | −28.57% |
| Q3 2022 | 2022-09-30 | $59.8M | −$37.8M | −38.75% |
| Q2 2022 | 2022-06-30 | $65.0M | −$40.4M | −38.32% |
| Q1 2022 | 2022-03-31 | $70.6M | −$41.2M | −36.85% |
| Q4 2021 | 2021-12-31 | $77.1M | $19.5M | +33.83% |
| Q3 2021 | 2021-09-30 | $97.6M | $32.3M | +49.58% |
| Q2 2021 | 2021-06-30 | $105.3M | $39.2M | +59.18% |
| Q1 2021 | 2021-03-31 | $111.8M | $43.0M | +62.58% |
| Q4 2020 | 2020-12-31 | $57.6M | −$19.9M | −25.64% |
| Q3 2020 | 2020-09-30 | $65.2M | −$45.6M | −41.14% |
| Q2 2020 | 2020-06-30 | $66.2M | −$54.1M | −44.99% |
| Q1 2020 | 2020-03-31 | $68.8M | −$61.0M | −47.01% |
| Q4 2019 | 2019-12-31 | $77.5M | −$61.6M | −44.30% |
| Q3 2019 | 2019-09-30 | $110.8M | −$39.7M | −26.38% |
| Q2 2019 | 2019-06-30 | $120.3M | −$40.7M | −25.26% |
| Q1 2019 | 2019-03-31 | $129.8M | −$44.7M | −25.60% |
| Q4 2018 | 2018-12-31 | $139.1M | −$44.6M | −24.26% |
| Q3 2018 | 2018-09-30 | $150.5M | −$43.0M | −22.21% |
| Q2 2018 | 2018-06-30 | $160.9M | $33.6M | +26.35% |
| Q1 2018 | 2018-03-31 | $174.5M | $39.2M | +28.94% |
| Q4 2017 | 2017-12-31 | $183.7M | $50.8M | +38.18% |
| Q3 2017 | 2017-09-30 | $193.5M | $51.8M | +36.54% |
| Q2 2017 | 2017-06-30 | $127.4M | −$19.1M | −13.05% |
| Q1 2017 | 2017-03-31 | $135.3M | $40.9M | +43.29% |
| Q4 2016 | 2016-12-31 | $132.9M | $50.4M | +60.99% |
| Q3 2016 | 2016-09-30 | $141.7M | $52.4M | +58.67% |
| Q2 2016 | 2016-06-30 | $146.5M | $52.2M | +55.32% |
| Q1 2016 | 2016-03-31 | $94.4M | −$7.4M | −7.28% |
| Q4 2015 | 2015-12-31 | $82.6M | $14.1M | +20.64% |
| Q3 2015 | 2015-09-30 | $89.3M | $16.0M | +21.81% |
| Q2 2015 | 2015-06-30 | $94.3M | $41.4M | +78.12% |
| Q1 2015 | 2015-03-31 | $101.8M | — | — |
| Q4 2014 | 2014-12-31 | $68.5M | $39.3M | +134.62% |
| Q3 2014 | 2014-09-30 | $73.3M | — | — |
| Q2 2014 | 2014-06-30 | $53.0M | — | — |
| Q4 2013 | 2013-12-31 | $29.2M | — | — |
Minerva Neurosciences total assets trends
Over the last five fiscal years, Minerva Neurosciences's total assets increased from $57.6M to $98.0M, a change of $40.3M. The latest reported quarter, Q2 2026, shows $95.1M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Minerva Neurosciences source filings ↗